# Renalys Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/renalys-pharma

- Industry: Biotechnology
- Headquarters: Chuo-ku, Japan
- Website: www.renalys.com/
- Total disclosed funding: $38M
- Latest round: Series A (Jul 18, 2024)
- Investors on record: 6

## About

Founded in 2024 and based in Tokyo, Japan, Renalys Pharma, Inc. operates as a biopharmaceutical company that develops drugs for end-stage renal diseases. The company was founded by its CEO, BT Slingsby, and CFO, Takeshi Takahashi. In January 2024, Catalys Pacific and SR One formed Renalys Pharma, Inc.

Renalys Pharma offers a clinical-stage biotechnology platform that develops drugs for patients with renal diseases in Asian countries. The firm develops treatments for chronic kidney disease (CKD) and end-stage renal disease (ESRD) in Japan and Asia. The company’s product line includes sparsentan, an oral dual endothelin angiotensin receptor antagonist (DEARA), which is a non-immunosuppressive therapeutic that develops drugs for IgA nephropathy patients.

The company plans to use the investment raised in January 2024 to expand its market reach locally and internationally.

## Funding rounds

- Series A, Jul 18, 2024, $38M — Sumitomo Mitsui Trust Bank, SR One, Nippon Venture Capital, Sumitomo Mitsui Trust Investment, Japan Post Investment Corporation, Catalys Pacific

## Investors

- Sumitomo Mitsui Trust Bank — Series A
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A
- Nippon Venture Capital (https://capitalatlas.ai/funds/nippon-venture-capital) — Series A
- Sumitomo Mitsui Trust Investment (https://capitalatlas.ai/funds/sumitomo-mitsui-trust-investment) — Series A
- Japan Post Investment Corporation — Series A
- Catalys Pacific (https://capitalatlas.ai/funds/catalys-pacific) — Series A